Embedded Micro-optic Security Features for Pharma and Other Applications

适用于制药和其他应用的嵌入式微光学安全功能

• 批准号: 10004480
• 金额: $ 28.73万
• 依托单位: OPTRICAL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10004480
• 关键词: Embedded; Micro; optic; Security; Features

As per the WHO report it is estimated that 10 to 15% of the world's drug supply is counterfeit and in 2017, 25million illicit and counterfeit drugs were seized by Interpol. Illicit supply of counterfeit medical items specially during a public health crisis can be catastrophic. Healthcare authorities worldwide have therefore developed regulations to counter the supply of fake drugs (e.g., European Delegated Regulation (EU) 2016/161, US falsification directive DSCSA or ISO standard 21976:2018). These regulations make a unique identifier sequence AND a device for the verification of any tampering essential for pharma packaging.To comply with these regulations, sophisticated serialisation and track/ trace systems have been developed globally over the past few years by assigning each pack a unique identifier. The availability of Tamper evidence features is however limited to security printed "Void" labels, holograms and custom package seals (e.g., NHS drugs are dispensed with self-adhesive labels with cross-cuts which break the label while peeling off), these measures however only apply to external packaging.In developing countries where medicines are sold "loose" (as individual tablets from a strip) unless the counterfeit measures are implemented on every blister/ strip pack, above regulations are of little significance! The best way of protecting every "tablet" from counterfeiting would be to embed an "easy to recognise but impossible to replicate" security feature in each blister/ strip pack during their manufacturing. Unfortunately, existing security feature like holograms, Fresnel lenses, diffractive features cannot be embedded as surface relief pattern responsible for the effect gets filled up.This project aims to bring inherently secure "easy to recognise and impossible to replicate", overt, dynamic, anti-counterfeit and tamper-evident features currently used only in high denomination currency notes (e.g., UK £50 and US $100 notes) first-time to pharma industry cost-effectively. Optrical has addressed some of the key challenges in developing this technology for external/ non-consumption applications. In this project we aim to develop the complete process for the production of such embeddable films on industrial scale and test the prototype for health safe/ pharma compliant product suiting the demands of medical industry.

根据世卫组织的报告，估计世界上10%至15%的药物供应是假药，2017年，国际刑警组织缴获了2500万份非法和假药。特别是在公共卫生危机期间，非法供应假冒医疗物品可能是灾难性的。因此，世界各地的医疗保健当局制定了法规来打击假药的供应（例如，欧洲授权法规（EU） 2016/161，美国伪造指令DSCSA或ISO标准21976:2018）。这些法规制定了唯一标识符序列和用于验证药品包装必要的任何篡改的设备。为了遵守这些规定，在过去几年中，通过为每个包装分配唯一标识符，全球开发了复杂的序列化和跟踪/跟踪系统。然而，篡改证据功能的可用性仅限于安全印刷的“Void”标签，全息图和定制包装密封（例如，NHS药物不使用带有交叉切口的不干胶标签，在剥离标签时会破坏标签），但这些措施仅适用于外部包装。在发展中国家，药品是“散装”销售的（作为单片片），除非在每个吸塑/条状包装上实施防伪措施，否则上述规定意义不大！保护每一个“平板电脑”不受假冒的最好方法是在制造过程中在每个吸塑/条形包装中嵌入一个“容易识别但不可能复制”的安全功能。不幸的是，现有的安全功能，如全息图，菲涅耳透镜，衍射特征不能嵌入，因为负责效果的表面浮雕图案被填满了。该项目旨在将目前仅用于高面额纸币（如50英镑和100美元纸币）的固有安全性“易于识别且无法复制”、公开、动态、防伪和防篡改的特征首次经济有效地引入制药行业。optical已经解决了在开发用于外部/非消费应用的这项技术的一些关键挑战。在这个项目中，我们的目标是在工业规模上开发这种可嵌入薄膜的完整生产过程，并测试符合医疗行业需求的健康安全/制药标准产品的原型。